Zentalis Pharmaceuticals Stock Options
| ZNTL Stock | USD 2.24 0.15 6.28% |
Zentalis Pharmaceuticals' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 2.0 with a put-to-call open interest ratio of 3.7 over 6 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on April 17th 2025. The total put volume is at 6.0, with calls trading at the volume of 20.0. This yields a 0.3 put-to-call volume ratio.
Open Interest Against April 17th 2025 Option Contracts
2025-04-17
The chart above shows Zentalis Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Zentalis Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Zentalis Pharmaceuticals' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Zentalis Pharmaceuticals
Analyzing Zentalis Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Zentalis Pharmaceuticals regardless of its overall volatility. This is especially true when Zentalis Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Zentalis Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Zentalis Pharmaceuticals' stock while costing only a fraction of its price.
Zentalis Current Options Market Mood
Zentalis Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Zentalis Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Zentalis Pharmaceuticals' options investors are not very successful. Zentalis Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Zentalis contract
Base on the Rule 16, the options market is currently suggesting that Zentalis Pharmaceuticals Llc will have an average daily up or down price movement of about 0.13% per day over the life of the 2025-04-17 option contract. With Zentalis Pharmaceuticals trading at USD 2.24, that is roughly USD 0.0028. If you think that the market is fully incorporating Zentalis Pharmaceuticals' daily price movement you should consider buying Zentalis Pharmaceuticals Llc options at the current volatility level of 2.0%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Zentalis |
Purchasing Zentalis Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Zentalis calls. Remember, the seller must deliver Zentalis Pharmaceuticals Llc stock to the call owner when a call is exercised.
Zentalis Pharmaceuticals Option Chain
When Zentalis Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Zentalis Pharmaceuticals Llc stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Zentalis Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Zentalis. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Zentalis. It also shows strike prices and maturity days for a Zentalis Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | ZNTL250417C00002500 | 21 | 2.5 | 0.55 - 2.3 | 2.6 | Out |
Call | ZNTL250417C00005000 | 179 | 5.0 | 0.2 - 2.5 | 0.25 | Out |
Call | ZNTL250417C00007500 | 27 | 7.5 | 0.0 - 4.9 | 0.3 | Out |
Put | ZNTL250417P00002500 | 839 | 2.5 | 0.7 - 0.8 | 0.75 | In |
Put | ZNTL250417P00005000 | 2 | 5.0 | 1.1 - 3.2 | 2.95 | In |
Put | ZNTL250417P00007500 | 0 | 7.5 | 4.0 - 8.0 | 4.0 | In |
Zentalis Total Stockholder Equity
Total Stockholder Equity |
|
Zentalis Pharmaceuticals Corporate Management
| Vincent Vultaggio | VP Officer | Profile | |
| Kevin Bunker | CoFounder Officer | Profile | |
| Carrie MD | Chief Officer | Profile | |
| Adrian MD | Executive Development | Profile | |
| Mark Lackner | Chief Strategy | Profile | |
| Ingmar MD | Chief Officer | Profile | |
| Kimberly Freeman | Chief Officer | Profile |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.